Personalis (NASDAQ:PSNL) CFO Sells $449,292.42 in Stock

Personalis, Inc. (NASDAQ:PSNL) CFO Aaron Tachibana sold 38,799 shares of the company’s stock in a transaction that occurred on Friday, May 29th. The shares were sold at an average price of $11.58, for a total transaction of $449,292.42. Following the sale, the chief financial officer directly owned 198,833 shares of the company’s stock, valued at approximately $2,302,486.14. This represents a 16.33% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Personalis Stock Performance

Shares of Personalis stock traded up $0.42 on Friday, hitting $11.40. 4,471,474 shares of the company’s stock were exchanged, compared to its average volume of 2,505,722. The company has a 50-day simple moving average of $6.86 and a 200-day simple moving average of $8.10. The stock has a market capitalization of $1.19 billion, a PE ratio of -11.18 and a beta of 1.96. Personalis, Inc. has a 1 year low of $3.84 and a 1 year high of $11.85.

Personalis (NASDAQ:PSNL) last posted its quarterly earnings data on Thursday, May 7th. The company reported ($0.29) EPS for the quarter, missing the consensus estimate of ($0.23) by ($0.06). Personalis had a negative return on equity of 43.52% and a negative net margin of 148.11%.The company had revenue of $15.47 million during the quarter, compared to analysts’ expectations of $14.49 million. On average, analysts expect that Personalis, Inc. will post -1.06 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on the company. Wall Street Zen cut Personalis from a “hold” rating to a “sell” rating in a report on Saturday, May 9th. Needham & Company LLC raised their target price on Personalis from $10.00 to $12.00 and gave the stock a “buy” rating in a report on Friday, February 27th. BTIG Research decreased their target price on Personalis from $13.00 to $11.00 and set a “buy” rating on the stock in a report on Monday, May 11th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Personalis in a report on Tuesday, April 21st. Finally, Morgan Stanley reduced their price objective on shares of Personalis from $10.00 to $9.00 and set an “equal weight” rating for the company in a research note on Tuesday, May 12th. Five research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $11.00.

Institutional Trading of Personalis

A number of hedge funds and other institutional investors have recently modified their holdings of PSNL. Royal Bank of Canada increased its stake in shares of Personalis by 3.2% in the first quarter. Royal Bank of Canada now owns 78,341 shares of the company’s stock worth $275,000 after purchasing an additional 2,395 shares in the last quarter. Dynamic Technology Lab Private Ltd increased its stake in shares of Personalis by 75.6% in the first quarter. Dynamic Technology Lab Private Ltd now owns 76,729 shares of the company’s stock worth $269,000 after purchasing an additional 33,044 shares in the last quarter. Goldman Sachs Group Inc. increased its stake in shares of Personalis by 55.7% in the first quarter. Goldman Sachs Group Inc. now owns 284,426 shares of the company’s stock worth $998,000 after purchasing an additional 101,706 shares in the last quarter. Focus Partners Wealth purchased a new stake in shares of Personalis in the first quarter worth $47,000. Finally, JPMorgan Chase & Co. increased its stake in shares of Personalis by 505.6% in the second quarter. JPMorgan Chase & Co. now owns 29,491 shares of the company’s stock worth $193,000 after purchasing an additional 24,621 shares in the last quarter. 61.91% of the stock is owned by hedge funds and other institutional investors.

About Personalis

Personalis, Inc (NASDAQ: PSNL) is a clinical‐stage genomics company that develops and markets advanced next‐generation sequencing (NGS) services and assays designed to accelerate precision medicine. The Company’s core offering is the ImmunoID NeXT™ Platform, which combines comprehensive tumor profiling—including whole exome, transcriptome, and T‐cell receptor sequencing—with proprietary bioinformatics to identify biomarkers and guide immuno‐oncology research. Personalis serves biopharmaceutical companies, academic institutions, and clinical research organizations seeking in‐depth insights into cancer, autoimmune diseases and other complex conditions.

In addition to its flagship ImmunoID NeXT™ Platform, Personalis offers a suite of customizable sequencing assays for biomarker discovery, clinical trial support and companion diagnostic development.